Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Trimel Pharmaceuticals announces completion of phase II TBS-2 trial in anorgasmia

Dec. 22, 2011

Ardea Biosciences initiates phase III lesinurad program

Dec. 22, 2011

Novel engineered physiocrine has thrombopoietic effects in vivo

Dec. 22, 2011

Roche discovers novel class of inhibitors of the hexosamine biosynthesis pathway

Dec. 22, 2011

CHMP issues recommendation on marketing authorization Esmya

Dec. 21, 2011

New fenofibrate products launched in Japan for hyperlipidemia

Dec. 21, 2011

Merck & Co. synthesizes new PRCP inhibitors

Dec. 21, 2011

Scientists at Mitsubishi Tanabe Pharma disclose new GPR119 receptor agonists

Dec. 21, 2011

New dipeptidyl peptidase 4 inhibitors patented by Chinese company

Dec. 21, 2011

FDA does not require REMS program for Korlym in Cushing's syndrome

Dec. 20, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...